Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;3(6):943-8.
doi: 10.2147/ndt.s2221.

Rivastigmine in Chinese patients with subcortical vascular dementia

Vincent Mok  1 , Adrian Wong, Simon Ho, Thomas Leung, Wynnie W M Lam, Ka Sing Wong
Affiliations

Rivastigmine in Chinese patients with subcortical vascular dementia

Vincent Mok et al. Neuropsychiatr Dis Treat. 2007 Dec.

Abstract

Background: We explored the efficacy and tolerability of rivastigmine among Chinese patients with subcortical vascular dementia.

Methods: Forty subjects were randomized to either placebo (n = 20) or rivastigmine (n = 20) in a double-blind 26-week trial. Outcome measures were cognition (mini-mental state examination, frontal assessment battery), neuropsychiatric inventory (NPI), instrumental activities of daily living, clinical dementia rating scale, and adverse events.

Results: No statistical significant benefit could be observed in the active group in any of the efficacy measures. A trend favoring active group was observed only in the NPI subscore of irritability (p = 0.066) and aberrant motor behavior (p = 0.068). Withdrawal rate was 30% and 15% in the active and placebo group, respectively.

Conclusion: Among Chinese subcortical vascular dementia patients, there was no apparent cognitive benefit associated with use of rivastigmine over the 6 months period. A trend favoring rivastigmine was observed in certain behavioral measures. Rivastigmine was associated with more withdrawals relative to placebo.

Keywords: Chinese; rivastigmine; subcortical vascular dementia.

PubMed Disclaimer

References

    1. Aharon-peretz J, Kliot D, Tomer R. Behavioral differences between white matter lacunar dementia and Alzheimer’s disease: a comparison on the neuropsychiatric inventory. Dement Geriatr Cogn Disord. 2000;11:294–8. - PubMed
    1. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323–30. - PubMed
    1. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin. 2005;21:1–10. - PubMed
    1. Chiu HF, Lam LC, Chi I, et al. Prevalence of dementia in Chinese elderly in Hong Kong. Neurology. 1998;50:1002–9. - PubMed
    1. Chiu HFK, Kee HC, Chung WS, et al. Reliability and validity of the Cantonese version of Mini-mental state examination – a preliminary study. Hong Kong Coll Psychiatry. 1994;4(S2):25–8.

LinkOut - more resources